Details:
Korlym (mifepristone) is an approved selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated in phase 4 for the treatment of cushing syndrome.
Lead Product(s): Mifepristone
Therapeutic Area: Endocrinology Product Name: Korlym
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.
Lead Product(s): Mifepristone
Therapeutic Area: Endocrinology Product Name: Korlym
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.
Lead Product(s): Mifepristone
Therapeutic Area: Endocrinology Product Name: Korlym
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Afrezza (human Insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist, which is investigated in combination with insulin degludec for the treatment of type 1 diabetes.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Product Name: Afrezza
Highest Development Status: Phase IV Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
Afrezza (human insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist and works as starts lowering blood sugars in ~12 minutes for adults living with type 1 or type 2 diabetes.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Product Name: Afrezza
Highest Development Status: Phase IV Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
JATENZO (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions, for the treatment of adult hypogonadal men with chronic kidney disease.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Jatenzo
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022